New Mexico Educational Retirement Board reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 12,300 shares of the life sciences company’s stock after selling 200 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Illumina were worth $3,821,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc lifted its position in Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after purchasing an additional 188,516 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Illumina by 66,581.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares in the last quarter. Jennison Associates LLC raised its position in shares of Illumina by 13.5% during the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Illumina by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after buying an additional 170,046 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Illumina during the 4th quarter worth about $514,627,000. Institutional investors own 90.46% of the company’s stock.
Illumina stock opened at $330.93 on Wednesday. The company has a market capitalization of $48.62 billion, a PE ratio of 57.85, a PEG ratio of 2.39 and a beta of 1.17. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a fifty-two week low of $226.62 and a fifty-two week high of $372.61.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The business’s revenue was up 11.4% on a year-over-year basis. During the same period last year, the business earned $1.44 earnings per share. On average, equities research analysts predict that Illumina, Inc. will post 6.53 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on ILMN shares. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 price objective on the stock in a research note on Friday, January 11th. Bank of America reaffirmed a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research note on Wednesday, January 30th. Deutsche Bank cut shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a research note on Friday, January 25th. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley lowered their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a research note on Monday, January 7th. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $346.97.
In related news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $317.01, for a total transaction of $1,046,133.00. Following the completion of the sale, the director now directly owns 331,668 shares in the company, valued at $105,142,072.68. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $280.11, for a total transaction of $34,733.64. Following the sale, the senior vice president now owns 6,879 shares of the company’s stock, valued at $1,926,876.69. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,826 shares of company stock worth $10,604,560. 0.54% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://macondaily.com/2019/04/17/new-mexico-educational-retirement-board-sells-200-shares-of-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Balance Sheet
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.